Ardabil University of Medical Sciences, Ardabil, Iran
Abstract: (24 Views)
IgA nephropathy, a leading form of primary glomerulonephritis globally, is marked by the accumulation of IgA-containing immune complexes in the glomerular mesangium, resulting in progressive kidney damage. The disease presents with diverse clinical features, including proteinuria, hematuria, and kidney failure, with varying progression among patients, making treatment particularly challenging. Due to its heterogeneity, treatment strategies are continually evolving, with a growing emphasis on personalized approaches guided by genetic data and biomarkers. This review highlights recent advancements in IgA nephropathy treatment, focusing on innovative therapies that have demonstrated potential in clinical trials or are under active investigation. Continued research and therapeutic breakthroughs hold promise for better symptom management and improved kidney outcomes.